CIK 0001819133 · Non-accelerated filer<br>Smaller reporting company
Tango Therapeutics, Inc.
Sign in to watch- Ticker
- TNGX
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- Phone
- (857) 320-4900
- Business address
- 201 BROOKLINE AVENUE, SUITE 901, BOSTON, MA, 02215
- Former names
- BCTG Acquisition Corp.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $1,858,086
- in 6 filings, $1.9M under 10b5-1 plans
Net −$1,858,086. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 18 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-09-08 | Third Rock Ventures IV, L.P. 10% owner | Sale | −86,459 | $7.04 | $609K | 14,727,516 |
| 2025-09-05 | Third Rock Ventures IV, L.P. 10% owner | Sale | −642,906 | $7.00 | $4.5M | 14,813,975 |
| 2025-08-22 | Third Rock Ventures IV, L.P. 10% owner | Sale | −302,194 | $7.00 | $2.1M | 15,456,881 |
| 2025-08-19 | Third Rock Ventures IV, L.P. 10% owner | Sale | −1,100,000 | $7.01 | $7.7M | 15,759,075 |
| 2025-06-05 | Peters Malte Director | Grant or award | +6,250 | 17,500 | ||
| 2025-06-05 | Peters Malte Director | Grant or award · Stock Option (Right to Buy) | +37,500 | 37,500 | ||
| 2025-06-05 | Calhoun Lesley Ann Director | Grant or award | +6,250 | 12,500 | ||
| 2025-06-05 | Calhoun Lesley Ann Director | Grant or award · Stock Option (Right to Buy) | +37,500 | 37,500 | ||
| 2025-06-05 | Rothenberg Mace Director | Grant or award | +6,250 | 37,500 | ||
| 2025-06-05 | Rothenberg Mace Director | Grant or award · Stock Option (Right to Buy) | +37,500 | 37,500 | ||
| 2025-06-05 | Ketchum John B Director | Grant or award | +6,250 | 20,937 | ||
| 2025-06-05 | Ketchum John B Director | Grant or award · Stock Option (Right to Buy) | +37,500 | 37,500 | ||
| 2025-06-05 | Borisy Alexis Director | Grant or award | +6,250 | 17,500 | ||
| 2025-06-05 | Borisy Alexis Director | Grant or award · Stock Option (Right to Buy) | +37,500 | 37,500 | ||
| 2025-02-05 | Barry Douglas General Counsel | Sale | −2,556 | $3.16 | $8K | 66,014 |
| 2025-02-05 | Beckman Daniella Chief Financial Officer | Sale | −3,948 | $3.16 | $12K | 150,284 |
| 2025-02-05 | Crystal Adam See Remarks | Sale | −6,851 | $3.16 | $22K | 158,210 |
| 2025-02-05 | Weber Barbara Chief Executive Officer | Sale | −9,013 | $3.16 | $28K | 1,622,251 |
| 2025-02-04 | Barry Douglas General Counsel | Sale | −2,774 | $2.99 | $8K | 68,570 |
| 2025-02-04 | Beckman Daniella Chief Financial Officer | Sale | −4,284 | $2.99 | $13K | 154,232 |
Page 5 of 11 · 211 trades